Endonovo Therapeutics, Inc. (ENDV)
| Market Cap | 219.58K |
| Revenue (ttm) | 255.72K |
| Net Income (ttm) | -4.40M |
| Shares Out | 1.10B |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,998,054 |
| Average Volume | 14,669,552 |
| Open | 0.0002 |
| Previous Close | 0.0002 |
| Day's Range | 0.0002 - 0.0002 |
| 52-Week Range | 0.0001 - 0.0027 |
| Beta | -1.70 |
| RSI | 48.16 |
| Earnings Date | Apr 15, 2025 |
About Endonovo Therapeutics
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery disea... [Read more]
Financial Performance
In 2022, Endonovo Therapeutics's revenue was $135,355, an increase of 85.15% compared to the previous year's $73,105. Losses were -$18.47 million, 495.0% more than in 2021.
Financial StatementsNews
Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Los Angeles, CA, March 28, 2024 (GLOBE NEWSWIRE) -- Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement (APA), ...
Endonovo's SofPulse® to Be Featured at Innovative Pain Management Solutions
US Army Medical Research and Development Command Vendor Day Los Angeles, CA, March 04, 2024 (GLOBE NEWSWIRE) -- SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off compa...
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives m...
Endonovo's SofPulse® Secures Taiwan FDA Approval
Los Angeles, CA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) US-based medical device company, today announced the full regulatory approval of its flagship product, SofP...
Endonovo's SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
Los Angeles, CA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a US-based commercial medical device company -- today announced its inclusion on the Federal Supply Sche...
Endonovo's Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
Los Angeles, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) -- commercial developer of medical technology-- is proud to announce a series of advancements in the first h...
Endonovo Pending Agreement to Develop Telehealth Division
Los Angeles, CA, June 07, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), an industry leading medical technology company, is working with a prominent developer of telehealth (telem...
Endonovo Launches SofPulse® into the Veterans Administration
Los Angeles, CA, May 02, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) a US-based biotechnology developer, today announced the launch of SofPulse® with Academy Medical, Inc., a Se...
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
Los Angeles, CA, April 25, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a leading developer of medical technologies, today announced it is moving forward in its clinical develop...
Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman
Los Angeles, CA, April 13, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial stage developer of non-invasive medical devices, is pleased to announce its partnership with...
Endonovo Announces Partnership with Santana Lead Singer Andy Vargas
Los Angeles, CA, April 10, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc (OTCQB: ENDV) -- a pioneer in bioelectronic medical devices -- announced today its partnership with world-renowned musicia...
Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company
Los Angeles, CA, March 29, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) today announced a binding Letter of Intent (LOI) to spin off its current medical device division to an enti...
Endonovo's SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in Taiwan
Los Angeles, CA, March 23, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a medical device company known for its innovative and effective pain management solutions -- announced ...
Olympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder Surgery
Los Angeles, CA, March 15, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced details today of the remarkable experience of one of its Scientific Advisory Board Members, Dr. ...
Endonovo Announces Distribution Agreement with Academy Medical
Provide Improved Medical Services to VHA and U . S . Dept . of Defense
Endonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira Weisberg
Los Angeles, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a medical device company specializing in pulsed electromagnetic field (PEMF) technology, announced today i...
Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off
Los Angeles, CA, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the retention of Ocean Tomo, a part of J.S. Held, to conduct a fairness opinion analysis in...
Endonovo Partners with International Distributor for SofPulse® Line
Partnership Expected to Increase SofPulse® Distribution and Revenues
New Details on Endonovo's Spin-Off of SofPulse, Inc.
Los Angeles, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced today details regarding the planned spin-off of its medical device assets to a newly formed Delaw...
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public Company
Los Angeles, CA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) today announced details for its plan to spin off its current medical device division, known as NewCo, as a s...
Endonovo Targets Dept. of Defense, VA & Federal Contracts
Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced the advancement of its aggressive “Go to Market” strategy for expansion of SofPulse® medical devi...
Endonovo Announces Advancement of International “Go to Market” Initiative
Los Angeles, CA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced an aggressive initiative to introduce and develop the sales and benefits of SofPulse® medic...
Endonovo Announces Plans for Spin-off of Medical IP and Assets
New Company To Be Formed for SofPulse ® Medical Device Line
Endonovo Launches Telehealth Initiative
Expand s Patient Education , Access to Non- Opioid Options f or Pain Management
Endonovo Names Ira Weisberg President to Guide Global Medical Expansion
Los Angeles, CA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today named Ira Weisberg as President and Chief Commercial Officer of its Medical Division.